Effects of cilostazol on the heart rate in healthy dogs

Fukushima, Ryuji; Kawaguchi, Takae; Yamada, Shusaku; Yoshimura, Aritada; Hirao, Daiki; Oomori, Takahiro

doi:10.1292/jvms.18-0240

Cited by 7 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dosages and timing of administration of cilostazol were selected based on past case reports ( 12 , 13 ), basic research ( 21 ), and the experience of the attending veterinarian. The most frequently used dose of cilostazol was 10.0–10.9 mg/kg twice daily (20.0–21.8 mg/kg/day).…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, cilostazol may be an effective treatment for sinus bradycardia, sinus arrest, and SSS, all of which are arrhythmias caused by sinus node dysfunction. We have previously demonstrated that cilostazol significantly reduces the PQ interval in dogs, which indicates that this agent influences AV conduction time but not the QT interval ( 21 ). Therefore, cilostazol may be effective in patients with maintained AV conduction or in patients with abnormal but not yet completely disrupted AV conduction.…”

Section: Discussionmentioning

confidence: 98%

“…In previous experiments in dogs ( 21 ) and in clinical reports ( 12 , 13 , 40 , 41 ) the dose of cilostazol used was 5–10 mg/kg twice daily. However, there has been no relevant prospective or retrospective clinical study with a large sample.…”

Section: Discussionmentioning

confidence: 99%

“…The subjects were divided into groups according to the cilostazol dose administered, based on the methodology from a previous experimental study on healthy dogs: group A, 0–5.0 mg/kg; group B, 5.1–7.5 mg/kg; group C, 7.6–9.9 mg/kg; and group D, ≥10.0 mg/kg ( 21 ). A stratified analysis of survival time was performed using log-rank (Cochran-Mantel-Haenszel) tests, and Kaplan-Meier survival curves were constructed.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of cilostazol in canine bradyarrhythmia

et al. 2022

Self Cite

View full text Add to dashboard Cite

Recently, cilostazol, a phosphodiesterase III inhibitor, has been described as alternative medical treatment for canine bradyarrhythmia in cases for which pacemaker implantation was not indicated or available. In this retrospective study, we investigated the use and efficacy of cilostazol in dogs with bradyarrhythmia in Japan. Dogs that had been brought to the Tokyo University of Agriculture and Technology Animal Medical Center and 23 veterinary hospitals in Japan and been treated with cilostazol initially as the only therapeutic strategy for bradyarrhythmia between January 2010 and August 2021 were included in this study. Survival analyses were performed using Cox proportional hazards analysis, the log-rank test, and the generalized Wilcoxon test to evaluate the efficacy of cilostazol. Fifty-nine privately owned dogs were included in this study. In the survival time analysis, the risk of death was significantly lower and the survival rate was higher in cases in which cilostazol was administered at 10 mg/kg or more per dose. A third-degree atrioventricular block also significantly increased the risk of death and was associated with a lower survival rate. However, in some patients with a third-degree atrioventricular block, there was an increase in the ventricular rate and improvement in clinical symptoms without disappearance or decrease of the atrioventricular block. This study had several important findings that have not previously been reported concerning the use of cilostazol for canine bradyarrhythmia, including the appropriate dose in a clinical setting and the efficacy and prognosis according to the type of bradyarrhythmia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of cilostazol in canine bradyarrhythmia

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 The abovementioned evidence indicates that cilostazol can be used to treat bradyarrhythmia. Although, cilostazol has been reported to increase the heart rate in healthy dogs, 15 and successfully treat sick sinus syndrome in a dog, the use of cilostazol has not been reported in cats. 16 The present study describes the clinical course and histological findings in a cat with high-grade AV block treated with cilostazol.…”

Section: Long-term Management Of High-grade Atrioventricular Block Usmentioning

confidence: 99%

Long-term management of high-grade atrioventricular block using cilostazol in a cat

Iwasa

Nishii

Takashima

et al. 2019

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 12-year-old neutered female domestic shorthair cat was admitted for syncope. Clinical signs and electrocardiography revealed high-grade atrioventricular (AV) block. Treatment with cilostazol ameliorated the clinical signs and arrhythmia. However, the high-grade AV block recurred on several occasions. After 640 days, the cat presented again with clinical deterioration owing to reoccurrence of the arrhythmia and it died 11 days later. Histopathological examination revealed a loss of conduction cells within the His bundle. Relevance and novel information To our knowledge, this is the first report of high-grade AV block treated with cilostazol in a cat. Treatment with cilostazol prolonged survival for 650 days without pacemaker implantation. Histological findings suggested that the AV block was related to fibrosis of the impulse conduction system.

show abstract

The anti-platelet drug cilostazol enhances interrenal steroidogenesis and exerts a scant effect on innate immune responses in zebrafish

Chang

Chen

Chuang

et al. 2022

Preprint

View full text Add to dashboard Cite

Rationale: Cilostazol, an anti-platelet phosphodiesterase-3 inhibitor used for the treatment of intermittent claudication, is known for its pleiotropic effects on platelets, endothelial cells and smooth muscle cells. However, how cilostazol impacts the endocrine system and the injury-induced inflammatory processes remains unclear. Methods: We used the zebrafish, a simple transparent model that demonstrates rapid development and a strong regenerative ability, to test whether cilostazol influences steroidogenesis, and the temporal and dosage effects of cilostazol on innate immune cells during tissue damage and repair. Results: While dosages of cilostazol from 10 to 100 uM did not induce any noticeable morphological abnormality in the embryonic and larval zebrafish, the heart rate and adrenal/interrenal steroidogenesis in larval zebrafish was increased in a dose-dependent manner. During larval fin amputation and regeneration, cilostazol treatments did not affect the immediate injury-induced recruitment of either neutrophils or macrophages, followed by a subtle yet significant effect on reducing the neutrophil retention at the lesion site. Conclusions: Our results indicate that cilostazol has a significant effect on the growth and endocrine function of steroidogenic tissue; and a limited effect on the neutrophil retention without affecting neutrophil and macrophage recruitment during tissue damage and repair.

show abstract

Effects of cilostazol on the heart rate in healthy dogs

Cited by 7 publications

References 18 publications

Efficacy of cilostazol in canine bradyarrhythmia

Efficacy of cilostazol in canine bradyarrhythmia

Long-term management of high-grade atrioventricular block using cilostazol in a cat

The anti-platelet drug cilostazol enhances interrenal steroidogenesis and exerts a scant effect on innate immune responses in zebrafish

Contact Info

Product

Resources

About